The SARS-CoV-2 Omicron variant (B.1.1.529) has multiple spike protein mutations 1 , 2 that
contribute to viral escape from antibody neutralization 3 , 4 , 5 – 6 and reduce vaccine …

SARS-CoV-2 variants that escape neutralization and potentially affect vaccine efficacy have
emerged. T cell responses play a role in protection from reinfection and severe disease, but …

Cross-Reactive Antibody Responses Elicited by the 501Y.V2 Variant Convalescent serum
from persons who had recovered from infection with 501Y.V2 (B.1.351), a SARS-CoV-2 …

The Johnson and Johnson Ad26.COV2.S single-dose vaccine represents an attractive option
for coronavirus disease 2019 (COVID-19) vaccination in countries with limited resources. …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants of concern (VOCs)
exhibit escape from neutralizing antibodies, causing concern about vaccine effectiveness. …

The SARS-CoV-2 Omicron variant has multiple Spike (S) protein mutations that contribute to
escape from the neutralizing antibody responses, and reducing vaccine protection from …

Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposures, from
infection or vaccination, can potently boost spike antibody responses. Less is known about the …

The Janssen (Johnson & Johnson) Ad26.COV2.S non-replicating viral vector vaccine has
been widely deployed for COVID-19 vaccination programs in resource-limited settings. Here …

Neutralization escape by SARS-CoV-2 variants, as has been observed in the 501Y. V2 (B.
1.351) variant, has impacted the efficacy of first generation COVID-19 vaccines. Here, the …

Ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolution has
given rise to recombinant Omicron lineages that dominate globally (XBB.1), as well as the …